Nanxin Li

Active 1990–2025

58
Papers
22,271
Citations
37
h-index
51
i10-index

Citations

Citations per year for Nanxin Li1948: 1 citations1990: 1 citations1991: 2 citations1992: 5 citations1993: 10 citations1994: 92 citations1995: 74 citations1996: 70 citations1997: 46 citations1998: 44 citations1999: 44 citations2000: 109 citations2001: 114 citations2002: 107 citations2003: 115 citations2004: 98 citations2005: 61 citations2006: 67 citations2007: 49 citations2008: 58 citations2009: 42 citations2010: 64 citations2011: 151 citations2012: 227 citations2013: 322 citations2014: 332 citations2015: 415 citations2016: 437 citations2017: 391 citations2018: 415 citations2019: 925 citations2020: 961 citations2021: 908 citations2022: 661 citations2023: 457 citations2024: 705 citations2025: 292 citations2026: 26 citations1949–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,011 citing papers, 33.5% of this breakdownChina: 1,489 citing papers, 12.5% of this breakdownUnited Kingdom: 649 citing papers, 5.4% of this breakdownGermany: 573 citing papers, 4.8% of this breakdownCanada: 453 citing papers, 3.8% of this breakdownJapan: 413 citing papers, 3.4% of this breakdownItaly: 389 citing papers, 3.2% of this breakdownFrance: 318 citing papers, 2.7% of this breakdownSwitzerland: 272 citing papers, 2.3% of this breakdownSpain: 260 citing papers, 2.2% of this breakdownSouth Korea: 246 citing papers, 2.1% of this breakdownAustralia: 235 citing papers, 2% of this breakdown
0%33.5%Other 22.1%

Fields

  • Biochemistry, Genetics and Molecular Biology37.6%
  • Medicine34.7%
  • Neuroscience13.6%
  • Computer Science7.1%
  • Psychology1.9%
  • Immunology and Microbiology1.6%
  • Other3.5%

Topics

  • Tryptophan and brain disorders4.9%
  • Treatment of Major Depression3.7%
  • Computational Drug Discovery Methods3.3%
  • Bioinformatics and Genomic Networks2.9%
  • Neuroscience and Neuropharmacology Research2.7%
  • Cancer Genomics and Diagnostics2.5%
  • Other80%

Coauthors

All papers

Open in search
  1. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway - Nature 2012 cited by 8,599

  2. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

    Authors: , , , , , , , , - Science 2010 cited by 2,915

  3. Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure

    Authors: , , , , , , , , - Biological Psychiatry 2011 cited by 1,084

  4. Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor

    Authors: , , , , , , , , , , , , , , , , , - Biological Psychiatry 2015 cited by 389

  5. The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2014 cited by 842

  6. Signaling pathways underlying the rapid antidepressant actions of ketamine

    Authors: , , , , - Neuropharmacology 2011 cited by 534

  7. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists

    Authors: , - Philosophical Transactions of the Royal Society B Biological Sciences 2012 cited by 359

  8. Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Todd Groessl, You-Qun He, Andrew Phimister, J. Alex Aycinena, Christian C. Lee, Badry Bursulaya, Donald S. Karanewsky, H. Martin Seidel, Jennifer L. Harris, Pierre‐Yves Michellys - Journal of Medicinal Chemistry 2013 cited by 412

  9. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 377

  10. Development of a rapid and sensitive fluorescent probe for high-throughput detecting SO2 in food samples

    Authors: , , , , , , - Food Chemistry 2023 cited by 22

  11. Is NF‐κB the sensor of oxidative stress?

    Authors: , - The FASEB Journal 1999 cited by 699

  12. Cognitive intervention for persons with mild cognitive impairment: A meta-analysis

    Authors: , , , , , - Ageing Research Reviews 2010 cited by 295

  13. Evidence of a disability paradox in patient‐reported outcomes in haemophilia

    Authors: , , , , , , , , , , - Haemophilia 2021 cited by 64

  14. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kalpana Jagtap, Michael D. Jones, Li Wang, Charlie Hatton, Emanuele Palescandolo, Supriya Gupta, Scott Mahan, Carrie Sougnez, Robert C. Onofrio, Ted Liefeld, Laura E. MacConaill, Wendy Winckler, Michael Reich, Nanxin Li, Jill P. Mesirov, Stacey Gabriel, Gad Getz, Kristin Ardlie, Vivien W. Chan, Vic E. Myer, Barbara L. Weber, Jeff Porter, Markus Warmuth, Peter M. Finan, Jennifer L. Harris, Matthew Meyerson, Todd R. Golub, Michael Morrissey, William R. Sellers, Robert Schlegel, Levi A. Garraway - Nature 2012 cited by 112

  15. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe

    Authors: , , , , , - Orphanet Journal of Rare Diseases 2021 cited by 29

  16. Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses

    Authors: , , , , , , , , , - Biological Psychiatry 2013 cited by 262

  17. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys

    Authors: , , , , - Orphanet Journal of Rare Diseases 2021 cited by 41

  18. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States

    Authors: , , , , , , , - Advances in Therapy 2023 cited by 25

  19. Is NF-kappaB the sensor of oxidative stress?

    Authors: , - 1999 cited by 788

  20. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

    Authors: , , , , , , , , , , , , , - Biochemical Journal 2010 cited by 179

  21. The scientific elucidation of daodi medicinal materials

    Authors: , , , , , , , , , , , , - Chinese Medicine 2020 cited by 51

  22. ATM Is Required for IκB Kinase (IKK) Activation in Response to DNA Double Strand Breaks

    Authors: , , , , , , , - Journal of Biological Chemistry 2001 cited by 188

  23. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

    Authors: , , , , , , , , , , , , , , , , , , - ACS Medicinal Chemistry Letters 2012 cited by 96

  24. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review

    Authors: , , , , , - Journal of Medical Economics 2019 cited by 39